share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hirawat Samit

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities

施贵宝 | 4：持股变动声明
SEC announcement ·  03/12 20:44
Moomoo AI 已提取核心信息
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
2024年3月10日，百时美施贵宝（BMY）执行副总裁、首席医学官兼药物开发主管萨米特·希拉瓦特完成了一系列涉及该公司普通股的交易。Hirawat通过免费行使衍生证券，共收购了38,388股股票。同时，他出售了25,354股股票。出售的股票包括用于支付行使价或纳税义务的股票，部分交易定价为每股53.79美元，总市值为734,179.71美元。这些交易之后，Hirawat直接持有的百时美施贵宝普通股为60,279股。
2024年3月10日，百时美施贵宝（BMY）执行副总裁、首席医学官兼药物开发主管萨米特·希拉瓦特完成了一系列涉及该公司普通股的交易。Hirawat通过免费行使衍生证券，共收购了38,388股股票。同时，他出售了25,354股股票。出售的股票包括用于支付行使价或纳税义务的股票，部分交易定价为每股53.79美元，总市值为734,179.71美元。这些交易之后，Hirawat直接持有的百时美施贵宝普通股为60,279股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息